Navigation Links
PAREXEL International Announces 2-For-1 Stock Split
Date:2/11/2008

gy industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward- looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

CONTACTS: James Winschel, Senior Vice President and Chief Financial

Officer

Jill Baker, Vice President of Investor Relations

+1-781-434-4118


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
2. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
3. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... British Columbia , March 2, 2015 ... IMLFF), a clinical stage biopharmaceutical company specializing in ... that Craig Schneider , Chief Executive Officer, ... webcast at VirtualInvestorConferences.com. DATE: Thursday, March ... > click the red "register/ watch event now" ...
(Date:3/2/2015)... -- Editor Note: For more information about ... Moments ago, Analysts Review released new research updates concerning several ... SSH ), Synergetics USA (NASDAQ: ... ), Spectranetics (NASDAQ: SPNC ), and Thoratec (NASDAQ: ... platform for investors, to hear about what matters - proudly ...
(Date:3/2/2015)... Kent, WA (PRWEB) March 02, 2015 ... tangential flow flat-sheet testing system at the 2015 AMTA ... is a culmination of a decade’s worth of engineering ... system compatible with a wide range of applications across ... be versatile enough to meet the dynamic needs of ...
(Date:3/1/2015)... 2015 Market Publishers Ltd and ... market research promotion on Internet. MarketPublishers.com is now ... out by DataGroup Booksellers. , Natalie Aster, Assistant ... commented on the recent partnership agreement as follows: ... our team of publishers. Since 1974, the company ...
Breaking Biology Technology:InMed Pharmaceuticals to Present Investor Webcast March 5 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Sterlitech Displays Complete CF042 Membrane Test System 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3
... to data may provide potential for label expansion in ... Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today an ... phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT data. ... appropriate for CTI to begin discussions with the,U.S. Food ...
... June 17 MEDRAD, INC., announced today,that ... new Fluorodeoxyglucose (FDG),Infusion System for Positron Emission ... PET Infusion System is the,first infusion system ... the FDG,delivery process., (Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO ...
... has published a,new report designed to provide critical ... stake in the market for diagnostics and treatments,in ... Insight &,Analysis: Alzheimer,s Disease," is based on in-depth ... actively involved in ongoing,research., "There is some ...
Cached Biology Technology:CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report 2
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... anaplastic lymphoma kinase, which has been reported in other ... a primary driver of the rapid metastasis that patients ... the use of anaplastic lymphoma kinase (ALK) inhibitors may ... lethal form of breast cancer. These data were ...
... scientist who is leading a multinational effort to improve ... an award for his work from the central Asian ... Academy of Natural Sciences of Drexel University, recently received ... his "significant contribution in Mongolian Environmental Science." The award ...
... press release is available in German . ... myriad smells in the air with the aid of odorant ... gene for expression. The probability that a particular receptor gene ... in total produce this receptor type. Scientists from the Max ...
Cached Biology News:Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Gene switch for odorant receptors 2Gene switch for odorant receptors 3
Polymerase (RNA) II (DNA directed) polypeptide L...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
Biology Products: